21 May 2020
Oncimmune Holdings plc
("Oncimmune" or the "Company")
EarlyCDT Lung Partnership Contract Signed
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that it has signed a foothill contract to utilise the Company's EarlyCDT Lung panel to detect incident lung cancer cases in a screening setting.
With one of the world's largest pharmaceutical companies, Oncimmune will further evaluate EarlyCDT Lung for the detection of lung cancer in at-risk patients. The initial phase of the collaboration will assess the utility of Early CDT Lung test at detecting incident lung cancer cases in a screening setting.
We expect this initial phase to be the first step towards a long term partnership to generate widespread availability of the EarlyCDT Lung test to improve early detection of lung cancer and facilitate earlier treatment.
Adam M Hill, CEO of Oncimmune said: "Over the past two months we have announced commercial contracts which touch upon the full breadth of Oncimmune's commercial offering. Our three year strategy, announced in late 2018, centred on identifying and capitalising upon the wide range of opportunities presented by Oncimmune's proprietary autoantibody-based platform. We firmly believe that the momentum we are building validates our strategy and underpins the commercial potential of our business.
We look forward to delivering this work over the coming weeks and announcing the further development of this partnership."
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
finnCap (Joint Broker)
Geoff Nash, Matthew Radley, Tim Redfern
+44 (0)20 7220 0500
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Ben Atwell, Michael Trace, Alex Davis
+44 (0)20 3727 1000
Beating cancer, one test at a time
The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.
Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 158,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS trial of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.
Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.
What is EarlyCDT Lung?
A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.
For more information, visit www.oncimmune.com